RegiSCAR DRESS Validation: Clinical scoring system for systemic drug hypersensitivity.
Clinical Validation Criteria
Fever ≥ 38.5°C
Enlarged Lymph Nodes (≥ 2 sites)
Eosinophilia (cells/μL)
Internal Organ Involvement
Ready to Validate
Enter the laboratory and clinical findings from the patient evaluation to determine the DRESS validation score.
Guidelines & Evidence
Verified
Last Review: 2026-07-17
When to Use
When to Use
The RegiSCAR scoring system provides a standardized, validated method to classify suspected Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) / Drug-Induced Hypersensitivity Syndrome (DIHS). Developed by the European RegiSCAR consortium and validated prospectively in a multinational cohort, it is used whenever DRESS enters the differential diagnosis of a severe febrile drug reaction.
Primary Indications
Suspected DRESS presenting 2–8 weeks after drug initiation with widespread rash, fever, and internal organ involvement
Differentiating DRESS from other SCARs: SJS/TEN and AGEP
Differentiating DRESS from viral exanthems (EBV, CMV, HHV-6 primary infection) and hypereosinophilic syndromes
Guiding need for systemic immunosuppression vs. watchful waiting in ambiguous presentations
Research and pharmacovigilance classification of severe drug reactions
When NOT to Use
AGEP — use the EuroSCAR AGEP validation score instead
SJS/TEN — use SCORTEN for mortality prediction; RegiSCAR DRESS criteria do not apply
Simple morbilliform drug eruptions without systemic features — not an appropriate use
As a substitute for clinical monitoring: serial labs are mandatory regardless of score category
Critical Alert
DRESS carries ~10% mortality from fulminant hepatitis, myocarditis, or pneumonitis. Discontinue the culprit drug immediately when DRESS is clinically suspected — do not await a definitive score.
How it Works
Scoring Criteria
| Fever ≥ 38.5°C | Yes = +1 | No = –1 |
| Enlarged lymph nodes (≥ 2 sites, > 1 cm) | Yes = +1 | No = 0 |
| Eosinophilia: 0.7–1.49 × 10⁹/L or 10–19.9% | +1 |
| Eosinophilia: ≥ 1.5 × 10⁹/L or ≥ 20% | +2 |
| Atypical lymphocytes on blood film | Yes = +1 | No = 0 |
| Skin rash extent > 50% BSA | +1 |
| Skin rash suggestive of DRESS (≥ 2 of: edema, infiltration, purpura, scaling) | +1 |
| Biopsy suggestive of DRESS | +1 |
| Internal organ involvement: 1 organ | +1 |
| Internal organ involvement: ≥ 2 organs | +2 |
| Resolution > 15 days after drug withdrawal | +1 |
| Exclusion of other causes (≥ 3 investigations negative: ANA, blood cultures, serology) | +1 |
Score Interpretation
| < 2 | No DRESS — diagnosis excluded |
| 2–3 | Possible DRESS |
| 4–5 | Probable DRESS |
| > 5 | Definite DRESS |
Pathophysiological Basis
DRESS results from impaired detoxification of reactive drug metabolites, triggering T-lymphocyte activation, a systemic cytokine storm, and sequential reactivation of latent herpesviruses — particularly HHV-6 (~60–70% of cases), EBV, and CMV. The immune response persists beyond drug withdrawal and can escalate for weeks. Internal organ damage — hepatitis, nephritis, myocarditis, and interstitial pneumonitis — is the primary driver of mortality.
Clinical Pearls
Diagnostic Pearls
DRESS classically presents 2–8 weeks after drug initiation — significantly later than morbilliform eruptions (7–14 days) or AGEP (< 4 days). Delayed onset is a cardinal feature.
Eosinophilia may be absent in the first 3–5 days of the rash. Serial CBCs every 48–72 hours are mandatory — a normal count at Day 1 does not exclude DRESS.
HHV-6 reactivation (rising serum PCR or seroconversion) occurs in ~60–70% of DRESS and correlates with more severe, protracted disease and higher relapse risk.
Commonest culprit drugs: aromatic antiepileptics (carbamazepine, phenytoin, lamotrigine), allopurinol, dapsone, sulfonamides, abacavir, nevirapine.
Patch testing and lymphocyte transformation tests (LTT) can identify the culprit drug but should be deferred ≥ 6 months post-resolution.
Score Limitations
Score is dynamic: early in the disease course, eosinophilia and organ involvement may not yet be present — repeat scoring as new data emerge over Days 5–10.
The "biopsy suggestive of DRESS" criterion requires expert dermatopathology and may not be specific in early disease.
Inter-rater variability exists for skin rash characteristics — standardized photographic training is recommended in research settings.
Differential Diagnosis
| DRESS vs. AGEP | AGEP: pustular rash, onset < 4 days, resolves < 15 days, rarely involves internal organs. Use AGEP EuroSCAR score. |
| DRESS vs. SJS/TEN | SJS/TEN: mucosal erosions, epidermal detachment, Nikolsky positive; rare eosinophilia. Use SCORTEN. |
| DRESS vs. viral exanthem | Primary EBV/CMV: monospot or serology positive; pharyngitis/splenomegaly; no culprit drug required. |
Guideline Position
The RegiSCAR score is referenced in the European Academy of Allergology and Clinical Immunology (EAACI) position paper on DRESS and is the most widely used classification tool in international pharmacovigilance databases. It was designed for case classification in research — all categories require expert clinical corroboration.
Next Steps
Management by Score Category
| < 2 — No DRESS | Re-evaluate for alternate diagnosis (viral exanthem, hypereosinophilic syndrome, other drug eruption). No specific DRESS therapy indicated. |
| 2–3 — Possible DRESS | Discontinue suspected drug. Serial CBC + LFTs + creatinine q48–72h. Dermatology and internal medicine review. Supportive topical TCS for cutaneous symptoms. |
| 4–5 — Probable DRESS | All of above + systemic corticosteroids (prednisolone 1–2 mg/kg/day) if hepatitis, pneumonitis, or myocarditis confirmed. HHV-6/EBV/CMV PCR panel. Ophthalmology (risk of uveitis). |
| > 5 — Definite DRESS | ICU-level monitoring if organ failure. High-dose systemic corticosteroids. IVIG or ciclosporin for steroid-refractory cases. Issue drug allergy card; counsel on lifelong avoidance of culprit and cross-reactive agents. |
Mandatory Investigations
01
Discontinue all suspected drugs immediately — no tapering, no delay
02
Serial CBC with differential (eosinophil count) every 48–72 hours for the first 2 weeks
03
LFTs, creatinine, CK, urinalysis — at baseline and every 48–72 hours
04
Viral serology: HHV-6 PCR and IgG, EBV VCA IgM/IgG, CMV IgM/IgG
05
Skin biopsy for histopathology if diagnosis uncertain
06
Echocardiogram if myocarditis suspected; HRCT chest + PFTs if respiratory symptoms
07
Thyroid function tests at 3 and 6 months post-resolution — autoimmune thyroiditis is a recognized delayed sequela
Relapse Warning
DRESS can relapse weeks to months after apparent resolution — particularly during steroid tapering. Taper prednisolone slowly over 3–6 months minimum. Counsel all patients to seek urgent review for any recurrence of rash or fever after discharge.
The Evidence
Original Derivation & Validation
Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?
Kardaun SH et al. • Br J Dermatol. 2007;156(3):609-611. RegiSCAR consortium paper proposing the scoring criteria and defining the DRESS diagnostic framework.
View SourceDrug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study.
Kardaun SH et al. • Br J Dermatol. 2013;169(5):1071-1080. Prospective multinational validation; n=172 classified cases; mortality ~10% in definite DRESS.
View SourceExternal Links
Origins & History
Origins
The RegiSCAR (Registry of Severe Cutaneous Adverse Reactions) scoring system was developed by the European RegiSCAR consortium — a multinational pharmacovigilance collaboration founded in 2001. Key contributors include Dr. S.H. Kardaun (University Medical Center Groningen, Netherlands), Dr. Jean-Claude Roujeau (Hôpital Henri Mondor, Créteil, France), and Dr. Maja Mockenhaupt (Dokumentationszentrum schwerer Hautreaktionen, Freiburg, Germany). The consortium prospectively registered severe cutaneous drug reactions across Europe with the goal of defining diagnostic criteria, identifying risk factors, and establishing causal drug-reaction associations. The DRESS scoring system was formally proposed in 2007 and validated prospectively in 2013, providing the first evidence-based classification framework for this heterogeneous and historically under-recognized syndrome.
Last Comprehensive Review: 2026-07-17